Fighting Infection

Closing the hygiene gap with 24/7 antimicrobial plastic technology

The year 2025 showed a sobering picture of our current public health resilience. As the year closed, NHS England reported that flu admissions surged by more than 55% in a single week, to 3,100 cases. At the same time novovirus hospitalisations followed a similarly aggressive trajectory, leaving national bed occupancy hovering at 94%. The strain on our clinical services is reaching a critical inflexion point, threatening to outpace national capacity.

While we look toward vaccines and pharmaceutical interventions as our primary shield, we are overlooking a fundamental weakness in our infrastructure: the very surfaces we touch every day. In the crowded environment of a hospital or a public transport system, every door handle, light switch, work-surface, floor, and wall acts as a potential vector for disease. Despite the efforts of frontline cleaning teams, we are fighting a losing battle against “point-in-time” hygiene – a reactive cycle, where a surface is only as safe as its last disinfectant wipe.

The recently published UKHSA Point Prevalence Survey starkly highlighted this persistent challenge. For the most vulnerable, such as orthopaedic patients and children, this figure can surge to as high as 16.6%. More than just statistics, these represent thousands of preventable infections and immense strain on the NHS.

Sepsis is a killer.

Therefore, it’s imperative that we no longer settle for reactive methods and instead move towards building 24/7 protection directly into the fabric.

Understanding the hygiene gap

The traditional approach to infection control relies heavily on manual intervention, but this is proving insufficient. When a surface is cleaned, it remains sterile for only a short time. This creates a window of several hours between cleaning cycles where pathogens can multiply, and spread – known as the hygiene gap. Human staff are being asked to provide a level of protection that is operationally impossible.

This gap is further amplified by real‑world behaviour and system pressures. High‑touch surfaces can be contacted hundreds or even thousands of times each day, often within moments of cleaning, while staff shortages, patient throughput and budget constraints make adequate cleaning impractical. Pathogens are shed continuously through touch, coughing, movement and equipment transfer, meaning re‑contamination begins immediately. The outcome is a predictable and systemic vulnerability.

The science of d2p and building resilience

Recognising that frequently touched surfaces can play an active role in spreading disease, we should now bring materials-science to the forefront of infection control. Symphony Environmental have developed d2p (designed-to-protect) technology to address this challenge, by embedding antimicrobial protection into the plastic itself. Rather than relying on spraying or wiping, d2p represents a permanent, science‑driven strategy rooted in polymer chemistry. See www.d2p.net

Coatings are vulnerable to abrasion, routine cleaning processes, or gradual chemical depletion through leaching, which can lead to uneven performance or a complete loss of efficacy. By contrast, d2p integrates anti-microbial performance into the plastic at the point of manufacture, using masterbatch technology. This ensures that antimicrobial functionality is distributed throughout the material, making it a stable and permanent characteristic rather than a temporary layer. As the surface wears, the underlying material retains the same properties, causing antimicrobial performance to remain consistent across the product’s full service life without compromising appearance, tactile properties, strength, or transparency.

The chemistry underpinning this process delivers molecular resilience, and pathogens cannot adapt or develop resistance in the way they might against antibiotics. It is lethal to pathogens but completely safe for people.

Technical efficacy of d2p at a glance

The reliability of d2p is backed by testing to internationally recognised standards:

· ISO 21702 (Antiviral): Independent laboratory tests have demonstrated a virus-reduction of 99.9% in as little as one hour. This is critical during winter surges when viral loads on communal surfaces are at their peak.

· ISO 22196 (Antibacterial): Tested against a formidable list of pathogens, including MRSA, E. coli, Salmonella, Listeria, and Pseudomonas. Results consistently show 99.99% efficacy.

· Regulatory Compliance: The active substances used in d2p are registered with the US Environmental Protection Agency (EPA) and comply with the EU’s Biocidal Products Regulation (BPR).

The economic reality

UK studies have estimated that a typical healthcare‑associated infection extends hospital stay by up to 11 days, at an average direct cost of around £5,000 per case. These figures reflect the treatment and isolation requirements, alongside bed opportunity-costs that compound rapidly under constrained capacity.

Breaking the Chain

The message for healthcare providers and plastics manufacturers is simple: the technology to reduce microbial risk already exists. It is mature, affordable at scale and compatible with existing manufacturing, recycling, and care‑delivery systems. What remains is the decision to deploy it systematically.

Antimicrobial plastics are not replacements for cleaning, staffing, or infection‑control protocols – far from it. Instead, they function as a permanent layer of resilience and a vital safety net, active all day every day.

The wider implications of antimicrobial plastic technology reach beyond healthcare environments. Antimicrobial packaging can reduce cross-contamination and foodborne disease, and Symphony’s d2p has been approved by the FDA in the US. In food supply chains, extending shelf life by using d2p in bread and produce packaging contributes directly to reducing food waste. Inhibiting mould and fungal growth during shipping increases resilience in humid conditions across global logistics.

Years on from the lessons of the COVID-19 pandemic, hygiene resilience is still a matter of public safety, system capacity and national preparedness. Seasonal surges, outdated infrastructure and constrained workforces leave little margin for passive design choices.

Universal adoption of d2p technology in hospitals and care homes and in many other settings is a tangible, effective strategy to address stubbornly high infection rates. It is an investment in hygiene resilience that quickly pays for itself by reducing the immense financial and human cost of preventable infections. The time for these changes is now, universal and urgent, before more people are needlessly harmed.

Your starting point is to visit Symphony’s website at www.d2p.net where you will see the full range of available technologies.